Lenvatinib plus pembrolizumab and chemotherapy did not significantly improve overall survival in metastatic ESCC compared to pembrolizumab and chemotherapy alone. Median overall survival was 17.6 ...

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patientsVision improvements were seen in both ...

G enentech, a member of the Roche Group, announced results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart compared with a ...

International travels should consider getting a burner phone to avoid border agents snooping on your private data.

Topline results and additional data from the pivotal SynAIRgy and LunAIRo Phase 3 studies – the largest clinical program of an investigational ...

The core functions of primary care are first contact access, comprehensiveness, continuity, coordination and ...

Objectives To investigate the occurrence of depression and mental health disorders other than depression among Brazilian people with intellectual disabilities, analysing data from a national household ...

The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

These rising investment bankers aged 35 and under have had key roles in major mergers, acquisitions, and IPOs.

Beyond its initial phase II trial results, stroke therapy developer Argenica has identified a clear path forward based on new data insights.